Microcurrent Stimulation 100ile Rent-To-Purchase Option - cost is $75 per month. First payment is $200 which includes $125 security, $75 for the first month security plus $10 shipping. Then the charge is $75 per month for the next 8 months until the unit is fully paid off. Total cost of the unit is $800.
100% of the rental and security is applied against the purchase price. User has the option to return the unit, and the user would only be charged $75 per month for the months used, and the security would be returned.
MicroCurrent Stimulation (MCS) is an enhanced adaptation of a FDA approved therapy used by anesthesiologists, orthopedic surgeons, plastic surgeons and rehabilitative specialists to promote the healing of wounds and transplanted tissues as well as to treat pain. User Experiences
HOW MCS WORKS
The theory is that MCS helps
- re-stimulate and energize dormant retinal cells (cells are like batteries -- when they run low in energy, they become sluggish and dormant),
- boost the cells' ability to rid themselves of waste products which interferes with the flow of energy, nutrients and communication,
- increase blood supply to the area stimulated. By increasing blood flow to the area, cells and tissues still living can get nourished and refreshed.
Although the exact mechanism of action of MCS has not yet been established scientifically, research suggests that microcurrent electrical stimulation device approximates the level of electrical activity present in a healthy eye, resulting in stimulating retinal activity and energizing dormant cells, as well as improving microvascular circulation, nerve conduction and velocity.
Microcurrent stimulation increases ATP (energy) synthesis in the retinal cells needed for membrane viability and waste management (a major concern for those with dry macular degeneration as excess waste not reabsorbed and eliminated results in waste accumulation called 'drusen').
The treatment of patients with Macular Degeneration and Retinitis Pigmentosa entails the periodic administration of very precise amounts of tightly controlled electrical current through electrodes applied to the skin at specific areas around the eye. The electrical current is used to stimulate the retina as well as the diseased macula in order to help protect sight. The procedure is safe, noninvasive and painless and no side effects or adverse reactions have been observed.
WHY WE OFFER THIS PARTICULAR UNIT:
This is the home unit version of the Microcurrent Stimulation (MCS 400) has the frequency settings that match those used in the studies described below. It is preset automatically to run through 4 frequencies in a preset 5-minute cycle before turning off. The four frequencies are: 292Hz for 30 seconds, 30Hz for 30 seconds, 9.1Hz for 2 minutes, then finally .3Hz for 2 minutes. Voltage is up to 22 and amps range 700 microAmps.
There are other microcurrent stimulation units available, but they have to be specifically calibrated both in frequency and timing to ensure proper gentle wave currents for your eyes. Most of these units are actually TENS units designed more for wound healing and bone repair.
IS MICROCURRENT STIMULATION SAFE:
No side effects or adverse outcomes related to this treatment have been seen so far. No increase in the conversion to the wet form of ARMD has been seen to those who have been treated.
In a consensus statement by the NIH reports that, 'One of the advantages...is that the incidence of adverse affects is substantially lower than that of many drugs or other accepted medical procedures used for the same conditions.'
STUDY SUMMARIES:The 1st three studies were summarized from the October, 2002 issue of the Townsend Newsletter:
The first study on MCS was a 2-year study done from 1983-1985 on 114 patients by Grace Halloran, Ph.D. The results of the study were as follows:
- 18 patients had Macular Degeneration, 16 improved.
- 78 had Retinitis Pigmentosa, 62 showed improvement.
- 18 patients had other various retinopathies, 16 improved.
- Of the ones that did not demonstrate any improvement, 14 stayed the same (although they otherwise would have been expected to lose vision), 2 continued to lose vision, although only slightly.
A ten-year clinical study was done by Drs. Jarding and Michael on the use of MCS to treat Macular Degeneration. Of the 400 eyes studied, the results were as follows:
- 78% of the eyes showed from 1-9 lines of improvement in reading of the visual acuity chart.
- Over 50% improved from 2-9 lines.
- In the study, 2 patients suffered from retinal vein occlusion and swelling of the macula. Both had dramatic improvement in vision.
Damon Miller, MD, reviewed the results of using Microcurrent Stimulation in the treatment of Stargardt's Disease, Retinitis Pigmentosa and other degenerative retinal diseases. His results indicate the following:
- That of the 120 patients treated, 83% showed improvement of greater than or equal to 2 lines of visual acuity in one or both eyes.
There are several metabolic processes that are enhanced through the use of Microcurrent Stimulation. The first to boost the cells' ability to rid themselves of waste products. A cell with 'stuck' waste products becomes a dead cell and interferes with cellular communication throughout the area where it is located. Cells need to take in nutrients and eliminate waste like all other living organisms. The energy supplied by Microcurrent Stimulation innervates cells to become vital and less sluggish.
The second way Microcurrent Stimulation works is by increasing blood supply to the area stimulated. By increasing blood flow to the area cells and tissues are nourished, refreshed and oxygenation is increased.
In general, the electrical current gently wakes up the cells from sleep and stimulates the healing process.
As its premier research project newly announced, the Macular Degeneration Foundation plans to conduct a nationwide controlled clinical trial to define the vision-enhancing value of administering what it terms Microcurrent Stimulation (MCS). The Foundation's two-year preliminary MCS trial involving 120 patients resulted in an average of:
- 68% improvement over pre-treatment vision for patients with the dry macular degeneration.
- 58% improvement over pre-treatment vision for those with the wet form of macular degeneration.
- Among certain subsets of patients with dry disease the results were even more dramatic, with a third gaining 100 percent or more improvement and a sixth gaining 150 percent or m